<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684760</url>
  </required_header>
  <id_info>
    <org_study_id>B7981003</org_study_id>
    <secondary_id>2015-004857-41</secondary_id>
    <nct_id>NCT02684760</nct_id>
  </id_info>
  <brief_title>Bioavailability Study Of PF-06651600 In Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open Label, Single-dose 3-way Crossover Study To Evaluate The Relative Bioavailability Of A Solid Dose Formulation Of Pf-06651600 Under Fasting Conditions And The Effect Of A High Fat Meal On The Bioavailability Of The Solid Dosage Formulation Of Pf-06651600 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PF-06651600 is being developed for treatment of inflammatory bowel disease. This study will
      test the bioavailability of a solid dose formulation of PF-06651600 compared to an oral
      solution formulation under fasting conditions and the effect of a high fat meal on the
      bioavailability of the solid dose formulation of PF-06651600 in healthy subjects. Safety and
      tolerability of the tablet and oral solution formulations of PF-06651600 will be assessed
      under fasting and fed conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-06651600</measure>
    <time_frame>0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06651600</measure>
    <time_frame>0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Cmax) for PF-06651600</measure>
    <time_frame>0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half Life (t1/2) for PF-06651600</measure>
    <time_frame>0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Plasma Decay Half-Life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax) for PF-06651600</measure>
    <time_frame>0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Time to Reach Maximum Concentration (Tmax)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: PF-06651600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: PF-06651600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: PF-06651600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: PF-06651600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: PF-06651600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: PF-06651600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06651600</intervention_name>
    <description>PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.</description>
    <arm_group_label>Cohort 1: PF-06651600</arm_group_label>
    <arm_group_label>Cohort 2: PF-06651600</arm_group_label>
    <arm_group_label>Cohort 3: PF-06651600</arm_group_label>
    <arm_group_label>Cohort 4: PF-06651600</arm_group_label>
    <arm_group_label>Cohort 5: PF-06651600</arm_group_label>
    <arm_group_label>Cohort 6: PF-06651600</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male/female subjects between 18 and 55 years old, inclusive. Females must be
             of non-child bearing potential.

          -  BMI of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  Prior history of chicken pox.

          -  Evidence of personally signed and dated informed consent document.

          -  Willing and able to comply with scheduled visits, treatment plan, lab tests and other
             study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, GI, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.

          -  History of regular alcohol consumption exceeding 14 drinks/week for females or 21
             drinks/week for males.

          -  Screening blood pressure &gt;140/90 mm Hg.

          -  Screening laboratory abnormalities as defined by the protocol.

          -  Unwilling or unable to comply with the Lifestyle Guidelines as defined by the
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7981003&amp;StudyName=A+Phase+1%2C+Open+Label%2C+Single-dose+3-way+Crossover+Study+To+Evaluate+The+Relative+Bioavailability+Of+A+Solid+Dose+Formulation+Of+Pf-06651600+Under+Fasting+Conditions+And+The+Effect+Of+A+High+Fat+Meal+On+The+Bioavailability+Of+The+Solid+Dosage+Formulation+Of+Pf-06651600+In+Healthy+Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

